BusinessEsperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic AcidBy Nasdaq OMXJan 8, 2017, 9:00 PM UTC
BusinessEsperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature CommunicationsBy Nasdaq OMXNov 28, 2016, 9:30 PM UTC
BusinessEsperion Therapeutics to Present at the Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 9, 2016, 9:30 PM UTC
BusinessEsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 3, 2016, 8:06 PM UTC
BusinessEsperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXNov 3, 2016, 8:06 PM UTC
BusinessEsperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare ConferenceBy Nasdaq OMXNov 1, 2016, 8:30 PM UTC
BusinessBempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any DoseBy Nasdaq OMXOct 13, 2016, 11:30 AM UTC